South Korean stocks experienced a dramatic plunge, exceeding 8% and triggering a trading halt. This sharp decline was primarily driven by a...

India is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...

The leap to a $5 trillion valuation for Nvidia underscores a dramatic paradigm shift: semiconductors have become the driving force of globa...

SpaceX shares fell another 3%, extending a three-day selloff that has wiped out over $600 billion in market value and pushed the stock belo...

Elon Musk's net worth has dropped by an estimated $350 billion after SpaceX shares tumbled more than 30% from their post-IPO peak, wiping o...

Mukesh Ambani's Reliance group is set to significantly boost its market presence, potentially holding nearly 7% of BSE's total market capit...

The green economy has hit a record $10 trillion market value. Revenue from climate solutions grew significantly last year. Companies focuse...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

Electronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

SpaceX has priced its record-breaking U.S. IPO at $135 per share, raising $75 billion and valuing the company at $1.77 trillion. This makes...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...